Jpmorgan Reiterates Shattuck Labs Rating on Dr3 - Jul 24

The Story

JPMorgan reiterated its stock rating for Shattuck Labs in a report focused on the company's DR3 program, according to Investing.com. The report did not include a quoted ticker or a current price in the Investing.com summary.

Why It Matters For Your Portfolio

• Analyst stance unchanged: JPMorgan's reiteration signals stability in the firm's view, which may limit immediate volatility from this note for $STTK if you hold the name.
• Valuation inputs highlighted: the report cites data points 64.50%, 28.26% and 3.59%, which investors can plug into discounted cash flow or relative valuation models to test scenarios.
• Multiple data points available: having 3 discrete percentages gives you different sensitivity checks for upside, downside, and probability-weighted outcomes.
• Limited immediate news flow: reiteration rather than an upgrade or downgrade suggests any material move will depend on clinical readouts or fresh analyst commentary rather than this note alone.

The Trade

Short-term traders should watch for follow-up analyst notes or any DR3 program updates that provide concrete readouts. Growth investors and valuation-focused investors can use the 64.50%, 28.26% and 3.59% figures to run scenario analyses; monitor upcoming clinical milestones, regulatory filings, and subsequent analyst commentary for clearer signals.